Clinical trials: Pembrolizumab
Neoplasm Malignant, Neoplasm, Experimental
Phase 1 First-in-human Study of JS014
This phase 1, first-in-human study uses a BOIN design to assess the safety and potential efficacy of JS014 at different dose levels as a single agent and in combination with fixed dose of pembrolizumab in subjects with advanced…
- Conditions
- Neoplasm Malignant, Neoplasm, Experimental, Solid Tumor, Adult, Lymphoma
- Trial name
- NCT05296772
- Testing
- JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody, Pembrolizumab - anti-PD-1 antibody
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Anwita Biosciences
Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
This phase II trial studies how well pembrolizumab works in treating patients with B-cell non-Hodgkin lymphoproliferative diseases that have not been treated.
- Conditions
- Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03498612
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
- Trial name
- NCT02506153
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 576 sites in United States, Canada and 1 more
- Volunteers
- 1,301 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
Pembrolizumab + Defactinib In Pleural Mesothelioma
This research study is studying a new drug combination of Pembrolizumab and Defactinib followed by surgical resection possible treatment for resectable Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT04201145
- Testing
- Pembrolizumab, Defactinib
- Where
- 2 sites in United States
- Sponsor
- Raphael Bueno, MD
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its maximum…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04344795
- Testing
- TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 89 people
- Sponsor
- Tempest Therapeutics
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
- Trial name
- NCT03325101
- Testing
- Cryosurgery, Pembrolizumab, Pheresis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Non-squamous, Non-Small Cell Lung Cancer
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer.
- Trial name
- LuTK03 (NCT07660094)
- Testing
- Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Candel Therapeutics, Inc.
Esophageal Adenocarcinoma
Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of…
- Trial name
- NCT02998268
- Testing
- Pembrolizumab, Taxol, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Weill Medical College of Cornell University
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer.
- Trial name
- URCOH-PMS-001 (NCT02733250)
- Testing
- Pembrolizumab, Nab-Paclitaxel
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Solid Tumors
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
- Trial name
- KEYNOTE-603 (NCT03313778)
- Testing
- mRNA-4157, Pembrolizumab, SoC Treatment
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 161 people
- Sponsor
- ModernaTX, Inc.
Endometrial Carcinoma, Cervix Carcinoma
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial…
- Trial name
- GYNET (NCT04652076)
- Testing
- NP137, Pembrolizumab, Paclitaxel
- Where
- 15 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- NETRIS Pharma
Breast Cancer
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or…
- Trial name
- NCT05852691
- Testing
- Tobemstomig, Pembrolizumab, Nab-Paclitaxel
- Where
- 36 sites in United States, Argentina and 14 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and occurs in the oral cavity, pharynx and larynx.
- Trial name
- ERBIOTAX (NCT06856213)
- Testing
- Cetuximab, Paclitaxel
- Where
- 17 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Advanced Solid Tumor
Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)
In this study, participants with advanced solid tumors were assigned to receive escalating doses of either MK-1248 alone or MK-1248 in combination with pembrolizumab (MK-3475).
- Trial name
- NCT02553499
- Testing
- MK-1248, pembrolizumab
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Classic Hodgkin Lymphoma
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma who aren't candidates for…
- Trial name
- NCT07275216
- Testing
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- City of Hope Medical Center
Melanoma, Stage II, Melanoma Stage III
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
Melanoma is a kind of skin cancer that starts in the melanocytes. Melanocytes are cells that make the pigment that gives skin its colour. 'Resected' means the melanoma has been completely removed with surgery.
- Trial name
- Dahlia (NCT06551064)
- Testing
- FYB206, Keytruda
- Where
- 17 sites in Bosnia and Herzegovina, Bulgaria and 9 more
- Volunteers
- 96 people
- Sponsor
- Formycon AG
Advanced Solid Tumor
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid…
- Trial name
- NCT06249048
- Testing
- STX-001, Keytruda®
- Where
- 7 sites in United States, Australia
- Volunteers
- 108 people
- Sponsor
- Strand Therapeutics Inc.
Triple Negative Breast Cancer
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for…
- Trial name
- NCT04427293
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Carcinoma, Hepatocellular
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma…
- Trial name
- NCT03062358
- Testing
- pembrolizumab, best supportive care (BSC)
- Where
- 41 sites in China, Hong Kong and 3 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.